Ablexis Announces Licensing Agreement with Corvidia Therapeutics

Ablexis grants rights to Corvidia to use the AlivaMab Mouse^™ platform for research, development and potential commercialization of antibodies

SAN DIEGO, Calif. – January 3, 2019 – Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Corvidia Therapeutics Inc. The non-exclusive license grants Corvidia rights to use the AlivaMab Mouse for antibody drug discovery and development. Financial terms of the license include an upfront payment, development milestones and a royalty on product sales.

About Ablexis, LLC

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at info@ablexis.com

Media Contact:

Christine Quern
cq@christinequern.com
617-650-8497